Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Rapamycin Cream for Facial Angiofibromas in TSC
NCT03826628Phase 3Completed
- Start
- Jul 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of sirolimus in facial angiofibroma (3 arms). Primary endpoint: Percentage of Participants Obtaining Successful Treatment at 26 weeks. Started Jul 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
facial angiofibroma
Beyond the preview
Go deeper on NCT03826628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826628.